thymosin alpha-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Between 11% and 27% of cases of keratoconus will progress to a point where vision correction is no longer possible, thinning of the cornea becomes excessive, or scarring as a result of contact lens wear causes problems of its own, and a corneal transplantation or penetrating keratoplasty becomes required. Keratoconus is the most common grounds for conducting a penetrating keratoplasty, generally accounting for around a quarter of such procedures. The corneal transplant surgeon trephines a lenticule of corneal tissue and then grafts the donor cornea to the existing eye tissue, usually using a combination of running and individual sutures. The cornea does not have a direct blood supply, so the donor tissue is not required to be blood type matched. Eye banks check the donor corneas for any disease or cellular irregularities. The acute recovery period can take four to six weeks, and full postoperative vision stabilization often takes a year or more, but most transplants are very stable in the long term. The National Keratoconus Foundation reports that penetrating keratoplasty has the most successful outcome of all transplant procedures, and when performed for keratoconus in an otherwise healthy eye, its success rate can be 95% or greater. The sutures used usually dissolve over a period of three to five years, but individual sutures can be removed during the healing process if they are causing irritation to the person. In the US, corneal transplants (also known as corneal grafts) for keratoconus are usually performed under sedation as outpatient surgery.
=== Systemic therapies === Because many cases of AN are associated with metabolic dysfunction, improvement in weight or insulin sensitivity may coincide with changes in the skin. Metformin, which is widely used for insulin resistance and type 2 diabetes, has been reported in case series and observational studies to coincide with improvement in AN; however, high-quality randomized trials with AN as a primary outcome are not available. Glucagon-like peptide-1 (GLP-1) receptor agonists, used for obesity and diabetes, have also been associated with improvement in some individuals with AN in observational reports, likely secondary to changes in metabolic status. These medications are not used specifically to treat AN, and evidence remains indirect.
Teleostei (; from Ancient Greek τέλειος (téleios) 'complete' and ὀστέον (ostéon) 'bone'), members of which are known as teleosts (), is, by far, the largest group of ray-finned fishes (class Actinopterygii), with 96% of all extant species of fish. The Teleostei, which is variously considered a division or an infraclass in different taxonomic systems, include over 26,000 species that are arranged in about 40 orders and 448 families. Teleosts range from giant oarfish measuring 7.6 m (25 ft) or more, and ocean sunfish weighing over 2 t (2.0 long tons; 2.2 short tons), to the minute male anglerfish Photocorynus spiniceps, just 6.2 mm (0.24 in) long. Including not only torpedo-shaped fish built for speed, teleosts can be flattened vertically or horizontally, be elongated cylinders or take specialised shapes as in anglerfish and seahorses. The difference between teleosts and other bony fish lies mainly in their jaw bones; teleosts have a movable premaxilla and corresponding modifications in the jaw musculature which make it possible for them to protrude their jaws outwards from the mouth. This is of great advantage, enabling them to grab prey and draw it into the mouth. In more derived teleosts, the enlarged premaxilla is the main tooth-bearing bone, and the maxilla, which is attached to the lower jaw, acts as a lever, pushing and pulling the premaxilla as the mouth is opened and closed. Other bones further back in the mouth serve to grind and swallow food. Another difference is that the upper and lower lobes of the tail (caudal) fin are about equal in size.
Subcutaneous administration is the insertion of medications beneath the skin either by injection or infusion. A subcutaneous injection is administered as a bolus into the subcutis, the layer of skin directly below the dermis and epidermis, collectively referred to as the cutis. The instruments are usually a hypodermic needle and a syringe. Subcutaneous injections are highly effective in administering medications such as insulin, morphine, diacetylmorphine and goserelin. Subcutaneous administration may be abbreviated as SC, SQ, subcu, sub-Q, SubQ, SUBQ, or subcut. SUBQ is the preferred abbreviation to reduce the risk of misunderstanding and potential errors. Subcutaneous tissue has few blood vessels and so drugs injected into it are intended for slow, sustained rates of absorption, often with some amount of depot effect. Compared with other routes of administration, it is slower than intramuscular injections but still faster than intradermal injections. Subcutaneous infusion (as opposed to subcutaneous injection) is similar but involves a continuous drip from a bag and line, as opposed to injection with a syringe.
Sources: en.wikipedia.org
==== Metabolism ==== Minoxidil is a prodrug of minoxidil sulfate, which can be formed both systemically and locally within hair follicles. This active metabolite is 14-fold more potent than minoxidil in stimulating cysteine incorporation in cultured rodent hair follicles ex vivo. Similarly to minoxidil, it also stimulates hair follicle growth. Minoxidil is sulfated into minoxidil sulfate by at least four cytosolic sulfotransferase enzymes found in skin, scalp, smooth muscle, liver, and fibroblasts. The primary sulfotransferase involved in sulfation of minoxidil in hair follicles is SULT1A1, whereas in the liver, it is SULT2A1. Expression of this enzyme has been found to predict the effectiveness of topical minoxidil. Oral minoxidil is subject to first-pass metabolism, including rapid and extensive metabolism in the liver. A majority of orally administered minoxidil, about 90%, is metabolized in the liver via glucuronidation, hydroxylation, and sulfation, with glucuronidation being the primary metabolic pathway and minoxidil glucuronide being the predominant metabolite of minoxidil. Conversely, topical minoxidil bypasses the first pass through the liver and is not subject to first-pass metabolism. Similarly, sublingual minoxidil also bypasses first-pass metabolism.
One theory says the submarine sandwich was brought to the U.S. by Dominic Conti (1874–1954), an Italian immigrant who came to New York in the late-19th century. He supposedly named it "submarine roll" after seeing the recovered 1901 submarine called Fenian Ram in the Paterson Museum of New Jersey in 1928. His granddaughter said:
Green garlic is indicative of harvesting that has taken place before the cloves have ripened, 'soft' garlic is the term given to a harvested garlic that is fully developed, while damaged garlic, with a caramelized appearance inside, has been harvested too late and a result of frost. When the leaves turn yellow in color, harvesting may be initiated.
=== Bibliography === Barrett, Kim E. (2019). Ganong's review of medical physiology. Barman, Susan M.,, Brooks, Heddwen L., Yuan, Jason X.-J. (26th ed.). New York. ISBN 978-1-260-12240-4. OCLC 1076268769.{{cite book}}: CS1 maint: location missing publisher (link) Beger HG, ed. (2018). The pancreas: an integrated textbook of basic science, medicine, and surgery (third ed.). Hoboken, NJ. ISBN 978-1-119-18841-4. OCLC 1065547789.{{cite book}}: CS1 maint: location missing publisher (link) Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J (2015). Harrison's Principles of Internal Medicine (19 ed.). McGraw-Hill Professional. ISBN 978-0-07-180215-4. Ralston SH, Penman ID, Strachan MW, Hobson RP, eds. (2018). Davidson's principles and practice of medicine (23rd ed.). Elsevier. ISBN 978-0-7020-7028-0. Standring, Susan; Borley, Neil R.; et al., eds. (2008). Gray's anatomy: the anatomical basis of clinical practice (40th ed.). London: Churchill Livingstone. ISBN 978-0-8089-2371-8. Standring, Susan, ed. (2016). Gray's anatomy: the anatomical basis of clinical practice (41st ed.). Philadelphia. ISBN 978-0-7020-5230-9. OCLC 920806541.{{cite book}}: CS1 maint: location missing publisher (link) Young, Barbara; O'Dowd, Geraldine; Woodford, Phillip (2013). Wheater's functional histology: a text and colour atlas (6th ed.). Philadelphia: Elsevier. ISBN 978-0-7020-4747-3.
==== NMDA receptor activity ==== NMDA receptor activation is essential to producing the activity-dependent molecular changes involved in the formation of new memories. Following exposure to an enriched environment, BDNF and NR1 phosphorylation levels are upregulated simultaneously, probably because BDNF is capable of phosphorylating NR1 subunits, in addition to its many other effects. One of the primary ways BDNF can modulate NMDA receptor activity is through phosphorylation and activation of the NMDA receptor one subunit, particularly at the PKC Ser-897 site. The mechanism underlying this activity is dependent upon both ERK and PKC signaling pathways, each acting individually, and all NR1 phosphorylation activity is lost if the TrKB receptor is blocked. PI3 kinase and Akt are also essential in BDNF-induced potentiation of NMDA receptor function and inhibition of either molecule eliminated receptor BDNF can also increase NMDA receptor activity through phosphorylation of the NR2B subunit. BDNF signaling leads to the autophosphorylation of the intracellular domain of the TrkB receptor (ICD-TrkB). Upon autophosphorylation, Fyn associates with the pICD-TrkB through its Src homology domain 2 (SH2) and is phosphorylated at its Y416 site. Once activated, Fyn can bind to NR2B through its SH2 domain and mediate phosphorylation of its Tyr-1472 site. Similar studies have suggested Fyn is also capable of activating NR2A although this was not found in the hippocampus. Thus, BDNF can increase NMDA receptor activity through Fyn activation.
Sources: en.wikipedia.org
=== Trump administration claims === The Trump administration alleges the vessels destroyed were operated by narcoterrorists or members of cartels or gangs. The Guardian stated on 6 November 2025 that "governments and families of those killed in the US strikes on alleged drug boats have said many of the dead were civilians—primarily fishers." Sean Parnell stated that Department of Defense intelligence "consistently ... confirm[ed] that the individuals involved in these drug operations were narco-terrorists, and we stand by that assessment". Names and surnames of people missing and suspected killed in the strikes have rarely been made public and information has been repressed by the Venezuelan government, or families have avoided speaking out of fear. Dozens of those killed have not been identified; as of 8 November, those identified publicly include two Colombians, one Ecuadorian, two men from Trinidad and Tobago, and nine Venezuelans. The family of a Colombian fisherman presumably killed in the 15 September strike stated that Alejandro Andrés Carranza Medina, alias 'Coroncoro', was not trafficking drugs, but according to CBS News, "... media have reported that Carranza had a criminal record for stealing weapons in collusion with gangs". Colombia's El Tiempo reported that in 2015 he was "allegedly involved in the theft of 264 weapons from the Santa Marta Metropolitan Police"; El País stated that the alleged perpetrator "accepted the charges of conspiracy to commit a crime, embezzlement, falsification of public documents and aggravated theft".
It is injected once a month, after the first month having a double dose. The main reported side effects are injection site reactions, although there are a growing number of reports of severe side effects from a minority of patients. Approved by the FDA in February 2020, ubrogepant (Ubrelvy) is an oral medication manufactured by AbbVie. Also approved that month, eptinezumab (Vyepti), is an intravenous migraine prophylactic medication manufactured by Lundbeck. Rimegepant (Nurtec ODT) subsequently became the first oral CGRP receptor antagonist to be approved by the FDA for both acute migraine treatment (approved February 2020) and prevention of episodic migraine (approved June 2021). It is manufactured by Pfizer. In September 2021 the FDA approved Qulipta (atogepant), the first oral CGRP receptor antagonist approved to prevent chronic migraine. The phytocannabinoids delta-9 tetrahydrocannabinol (Δ9-THC) and its oxidative byproduct cannabinol (CBN) are found to induce a CB1 and CB2 cannabinoid receptor-independent release of calcitonin gene-related peptide from capsaicin-sensitive perivascular sensory nerves, an action that other psychotropic cannabinoids cannot do.
Artocarpus is a genus of approximately 60 trees and shrubs of Southeast Asian and Pacific origin, belonging to the mulberry family, Moraceae. Most species of Artocarpus are restricted to Southeast Asia; a few cultivated species are more widely distributed, especially A. altilis (breadfruit) and A. heterophyllus (jackfruit), which are cultivated throughout the tropics.
In June 2020, HHS announced an unusual agreement with Gilead in which HHS agreed to Gilead's wholesale acquisition price, HHS would continue to work together with state governments and drug wholesaler AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that three-month timeframe (July, August, and September), American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses. Absent from these announcements was any discussion of allocation of remdesivir production to the approximately 70 countries omitted from Gilead's generic drug licensing agreements—including much of Europe and countries as populous as Brazil, China, and Mexico—or the 127 countries listed on those agreements (during the time it will take for Gilead's generic licensees to ramp up their own production). As the implications of this began to sink in, several countries publicly confirmed the next day that they already had adequate supplies of remdesivir to cover current needs, including Australia, Germany, and the United Kingdom. In August 2020, the FDA broadened the Emergency Use Authorization (EUA) for remdesivir to include all hospitalized patients with suspected or laboratory-confirmed COVID‑19, irrespective of the severity of their disease. The Fact Sheet was updated to reflect the new guidance.
=== Electricity demand and grid capacity === The proliferation of AI has driven a surge in data centre construction and power requirements. According to the National Energy System Operator (NESO), UK data centres consumed 5.0 TWh of electricity in 2023, equivalent to 2% of total UK electricity demand and 7% of commercial sector consumption. However, Oxford Economics forecasts that total demand could grow more than fivefold by 2030, reaching 26.2 TWh, which would represent 8.8% of total UK electricity demand and 30.4% of commercial electricity consumption. This rapid growth has created friction with the UK's net zero targets. In February 2026, the Environmental Audit Committee raised concerns that the government had not adequately factored data centre energy consumption into the draft Seventh Carbon Budget. The energy regulator Ofgem disclosed that developers of new data centres had enquired about grid connections that would require more energy at peak times than the whole of Britain consumes on some days.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.